These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26853751)

  • 1. New Therapeutic Approaches to the Treatment of Dyslipidemia.
    Rader DJ
    Cell Metab; 2016 Mar; 23(3):405-12. PubMed ID: 26853751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
    Giunzioni I; Tavori H
    Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.
    Farnier M
    Curr Cardiol Rep; 2016 Jul; 18(7):65. PubMed ID: 27216845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
    Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective.
    Parhofer KG
    Atheroscler Suppl; 2015 May; 18():109-11. PubMed ID: 25936313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.
    Zhang H; de Aguiar Vallim TQ; Martel C;
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):e56-61. PubMed ID: 27335468
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
    Nordestgaard BG
    Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in PAD patients - a rising star in secondary prevention?
    Vasa; 2018 Feb; 47(2):157. PubMed ID: 29460708
    [No Abstract]   [Full Text] [Related]  

  • 13. Would Janus' view on HDL be useful?
    Kasko M; Kasko V; Oravec S
    Bratisl Lek Listy; 2018; 119(4):245-248. PubMed ID: 29663823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PCSK9 inhibitors: For which patients? For which indication? What to consider?].
    Busygina K; Parhofer KG
    MMW Fortschr Med; 2018 Jan; 160(1):43-46. PubMed ID: 29335943
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--Pro.
    Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):439-41. PubMed ID: 26848159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.